Contact
searchSearch
HMP Global
Login

Bladder Cancer Resource Center

Videos
Detecting Molecular Relapse After Immunotherapy in Urothelial Carcinoma and Renal Cell Carcinoma Using ctDNA
06/05/2025
Lingbin Meng, MD, PhD
Discover how ctDNA testing could revolutionize post-immunotherapy surveillance by detecting cancer relapse weeks before traditional imaging.
Discover how ctDNA testing could revolutionize post-immunotherapy surveillance by detecting cancer relapse weeks before traditional imaging.
Discover how ctDNA testing could...
06/05/2025
Journal of Clinical Pathways
FDA Approval
FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations
01/20/2024
Stephanie Holland
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1...
01/20/2024
Oncology
From Oncology
News
Endoluminal Gemcitabine-Docetaxel as a Renal-Sparing Option for Select Patients With High Grade Upper-Tract Urothelial Carcinoma
01/08/2024
Allison Casey
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective...
01/08/2024
Oncology
From Oncology
David Bogumil
Videos
Multiple Ethnicities Study Explores A Connection Between Type 2 Diabetes and Urinary Bladder Cancer
10/12/2023
David Bogumil
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his...
10/12/2023
Journal of Clinical Pathways
Conference Coverage
Outcomes and Costs of Treatment for Patients With Metastatic Upper Tract Urothelial Carcinoma
03/31/2023
Grace Taylor, MS, MA
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers...
03/31/2023
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Therapy Guidelines in Bladder Cancer
08/26/2022
Yvette C. Terrie, BS Pharm, RPh
NCCN Guidelines Panel for Bladder Cancer presented data evaluating new treatment options in bladder cancer, as well as relevant updates to the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer.
NCCN Guidelines Panel for Bladder Cancer presented data evaluating new treatment options in bladder cancer, as well as relevant updates to the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer.
NCCN Guidelines Panel for...
08/26/2022
Journal of Clinical Pathways
News
Increased Costs Associated With Excessive Surveillance and Treatment For Non–Muscle-Invasive Bladder Cancer
04/14/2022
Ellen Kurek
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost...
04/14/2022
Journal of Clinical Pathways
Research Reports
Overactive Bladder Health Care Burden in the US Long-Term Care Setting: A Retrospective Cohort Study
05/18/2021
Drishti Shah, PhD; Jason Yeaw, MPH; Amy Kincaid, MA; Paul N. Mudd, Jr., PharmD, MBA; Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Richard Stefanacci, DO, and colleagues describe and evaluate the population, treatment patterns, HCRU, and costs associated with overactive bladder in the in the US long-term care setting.
Richard Stefanacci, DO, and colleagues describe and evaluate the population, treatment patterns, HCRU, and costs associated with overactive bladder in the in the US long-term care setting.
Richard Stefanacci, DO, and...
05/18/2021
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Clinical Practice Guideline for Bladder Cancer
03/24/2021
Janelle Bradley
NCCN updated its clinical practice guideline for bladder cancer, removing atezolizumab as an alternative second-line systemic therapy option for locally advanced or metastatic disease.
NCCN updated its clinical practice guideline for bladder cancer, removing atezolizumab as an alternative second-line systemic therapy option for locally advanced or metastatic disease.
NCCN updated its clinical...
03/24/2021
Journal of Clinical Pathways
Videos
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
03/12/2021
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses...
03/12/2021
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Clinical Practice Guideline for Bladder Cancer
03/10/2021
On March 9, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for bladder cancer.
On March 9, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for bladder cancer.
On March 9, 2021, the National...
03/10/2021
Journal of Clinical Pathways

Expert Insights

Videos
Detecting Molecular Relapse After Immunotherapy in Urothelial Carcinoma and Renal Cell Carcinoma Using ctDNA
06/05/2025
Lingbin Meng, MD, PhD
Discover how ctDNA testing could revolutionize post-immunotherapy surveillance by detecting cancer relapse weeks before traditional imaging.
Discover how ctDNA testing could revolutionize post-immunotherapy surveillance by detecting cancer relapse weeks before traditional imaging.
Discover how ctDNA testing could...
06/05/2025
Journal of Clinical Pathways
David Bogumil
Videos
Multiple Ethnicities Study Explores A Connection Between Type 2 Diabetes and Urinary Bladder Cancer
10/12/2023
David Bogumil
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his...
10/12/2023
Journal of Clinical Pathways
Videos
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
03/12/2021
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses...
03/12/2021
Journal of Clinical Pathways
Videos
Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma
02/19/2021
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the...
02/19/2021
Journal of Clinical Pathways
Videos
Adoption of Avelumab for First-Line Maintenance Therapy of Urothelial Cancer in US
02/18/2021
02/18/2021
Journal of Clinical Pathways
Videos
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
02/17/2021
02/17/2021
Journal of Clinical Pathways
Olivia Lynch
Interview
Where Access Breaks Down: Uncovering Persistent Disparities in Early-Stage Lung Cancer Treatment
04/21/2026
Olivia Lynch, MD, MPH
A guest expert shares research findings about persistent racial disparities in access to curative treatment for early-stage lung cancer, pointing to systemic barriers that arise before patients ever reach the operating room.
A guest expert shares research findings about persistent racial disparities in access to curative treatment for early-stage lung cancer, pointing to systemic barriers that arise before patients ever reach the operating room.
A guest expert shares research...
04/21/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment: Part 2
03/24/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how...
03/24/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment
03/24/2026
Rahul Mudumba, PhD, MHS
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba...
03/24/2026
Journal of Clinical Pathways
Quality Outlook
Measuring Justice in Breast Cancer Screening: A Bioethical Framework for Analyzing Quality Measures
03/10/2026
Nandita Ammanamanchi, BA; Rachel Delinger, MPH; David Blaisdell, BA; Tom Valuck, MD, JD
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality...
03/10/2026
Journal of Clinical Pathways
Ovarian cancer, Rosella trial
Videos
Advancing Treatment in Platinum-Resistant Ovarian Cancer: Clinical Impact of the ROSELLA Trial
03/03/2026
Robert L. Colemen, MD, FACOG, FACS
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses...
03/03/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Examining Equity Gaps in Immune Checkpoint Inhibitor Trials for NSCLC
02/25/2026
Adam Barsouk, MD
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses...
02/25/2026
Journal of Clinical Pathways
Quality Outlook
The Rising and Setting of Health Equity
02/24/2026
David Sloan, PhD; Tom Valuck, MD, JD
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating...
02/24/2026
Journal of Clinical Pathways
JJN
Interview
NSCLC Clinical Pathways in the Era of Molecular Complexity, AI, and Value-Based Care
02/20/2026
Jorge J. Nieva, MD
In this interview, a guest expert discusses how clinical pathways in EGFR- and ALK-mutated non-small cell lung cancer (NSCLC) must adapt to growing molecular complexity, integrate emerging technologies such as artificial intelligence and...
In this interview, a guest expert discusses how clinical pathways in EGFR- and ALK-mutated non-small cell lung cancer (NSCLC) must adapt to growing molecular complexity, integrate emerging technologies such as artificial intelligence and...
In this interview, a guest...
02/20/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Interview
Reflex NGS and PD-L1 Testing Streamlines Biomarker Turnaround and Treatment Planning in Resectable NSCLC
01/27/2026
Tina Edmonston, MD; David D. Shersher, MD
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David...
01/27/2026
Journal of Clinical Pathways
Olalekan Oluwole, MD, MBBS
Conference Coverage
Time and Travel Impact of CAR T-Cell vs Bispecific Antibody Therapy for Patients With R/R DLBCL: Real-World Analysis
01/26/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS,...
01/26/2026
Oncology

Newsfeed

FDA Approval
FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations
01/20/2024
Stephanie Holland
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1...
01/20/2024
Oncology
News
Endoluminal Gemcitabine-Docetaxel as a Renal-Sparing Option for Select Patients With High Grade Upper-Tract Urothelial Carcinoma
01/08/2024
Allison Casey
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective...
01/08/2024
Oncology
Conference Coverage
Outcomes and Costs of Treatment for Patients With Metastatic Upper Tract Urothelial Carcinoma
03/31/2023
Grace Taylor, MS, MA
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers...
03/31/2023
Journal of Clinical Pathways
News
Increased Costs Associated With Excessive Surveillance and Treatment For Non–Muscle-Invasive Bladder Cancer
04/14/2022
Ellen Kurek
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost...
04/14/2022
Journal of Clinical Pathways
News
How Age, Comorbidities, and Race Influence Cancer Treatment in Older Patients
05/05/2026
Rebecca Amrick
Using the US Surveillance, Epidemiology, and End Results (SEER)-Medicare linkage database, a study identified potential gaps in geriatric oncology care among Black and Hispanic patients, older age groups, and patients with multimorbidity.
Using the US Surveillance, Epidemiology, and End Results (SEER)-Medicare linkage database, a study identified potential gaps in geriatric oncology care among Black and Hispanic patients, older age groups, and patients with multimorbidity.
Using the US Surveillance,...
05/05/2026
Journal of Clinical Pathways
News
Liquid Biopsies Show Promise but Face Key Challenges in Older Adults
04/29/2026
Lisa Kuhns, PhD, MD
Liquid biopsies hold promise for transforming cancer care in older adults—but age-related biological changes may complicate their accuracy and clinical use.
Liquid biopsies hold promise for transforming cancer care in older adults—but age-related biological changes may complicate their accuracy and clinical use.
Liquid biopsies hold promise for...
04/29/2026
Journal of Clinical Pathways
News
Just Released: 2026 Clinical Pathways Congress Agenda
04/23/2026
Danielle Sposato
Join us November 10–11, 2026 at the Four Seasons Hotel Boston as we bring together leaders across the pathways ecosystem for two days focused on turning strategy into action.
Join us November 10–11, 2026 at the Four Seasons Hotel Boston as we bring together leaders across the pathways ecosystem for two days focused on turning strategy into action.
Join us November 10–11, 2026 at...
04/23/2026
Journal of Clinical Pathways
News
Proactive Outreach for Smoking Cessation Treatment Shows Potential for Patients With Cancer
04/17/2026
Rebecca Amrick
A proactive smoking cessation program for patients with cancer shows high engagement and satisfaction among participants, but low enrollment highlights ongoing challenges with patient identification and outreach.
A proactive smoking cessation program for patients with cancer shows high engagement and satisfaction among participants, but low enrollment highlights ongoing challenges with patient identification and outreach.
A proactive smoking cessation...
04/17/2026
Journal of Clinical Pathways
News
Interventional Radiology Leads Multidisciplinary Care in Liver Cancer Treatment
04/15/2026
Lisa Kuhns, PhD, MD
Research suggests that interventional radiology is central to hepatocellular carcinoma (HCC) care at all stages.
Research suggests that interventional radiology is central to hepatocellular carcinoma (HCC) care at all stages.
Research suggests that...
04/15/2026
Journal of Clinical Pathways
News
Short-Duration Venetoclax Plus Decitabine Shows Comparable AML Outcomes
04/09/2026
Grace Taylor, MS, MA
A shortened 10-day venetoclax regimen combined with decitabine delivers comparable remission rates with fewer infections in older patients with newly diagnosed acute myeloid leukemia (AML).
A shortened 10-day venetoclax regimen combined with decitabine delivers comparable remission rates with fewer infections in older patients with newly diagnosed acute myeloid leukemia (AML).
A shortened 10-day venetoclax...
04/09/2026
Journal of Clinical Pathways
News
FDA Approves Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer
04/08/2026
Grace Taylor, MS, MA
The US Food and Drug Administration's (FDA) approval of relacorilant plus nab-paclitaxel offers a new survival-improving option for patients with platinum-resistant ovarian cancer following prior bevacizumab therapy.
The US Food and Drug Administration's (FDA) approval of relacorilant plus nab-paclitaxel offers a new survival-improving option for patients with platinum-resistant ovarian cancer following prior bevacizumab therapy.
The US Food and Drug...
04/08/2026
Journal of Clinical Pathways
News
Geographic Barriers Limit CAR T-Cell Therapy Access in US Medicare Patients With DLBCL
03/12/2026
Grace Taylor, MS, MA
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in...
03/12/2026
Journal of Clinical Pathways
News
Social Drivers Linked to Hepatocellular Carcinoma Stage and Survival in US Integrated Care System
03/09/2026
Hannah Musick
In a large integrated US health system, Asian and Pacific Islander patients with hepatocellular carcinoma (HCC) had lower odds of advanced-stage diagnosis and better 5-year survival, while residence in socioeconomically deprived neighborhoods...
In a large integrated US health system, Asian and Pacific Islander patients with hepatocellular carcinoma (HCC) had lower odds of advanced-stage diagnosis and better 5-year survival, while residence in socioeconomically deprived neighborhoods...
In a large integrated US health...
03/09/2026
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab Plus Paclitaxel for Platinum-Resistant Ovarian Cancer in the US
03/06/2026
Hannah Musick
The US Food and Drug Administration (FDA) has approved pembrolizumab in combination with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma, based on improved...
The US Food and Drug Administration (FDA) has approved pembrolizumab in combination with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma, based on improved...
The US Food and Drug...
03/06/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use